Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients
Abstract Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
---|---|
Enthalten in: |
Age - 46(2023), 2 vom: 01. Sept., Seite 1561-1574 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tóth, Emese [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Autoantibody |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1007/s11357-023-00887-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR054586704 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR054586704 | ||
003 | DE-627 | ||
005 | 20240131064705.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240131s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11357-023-00887-2 |2 doi | |
035 | |a (DE-627)SPR054586704 | ||
035 | |a (SPR)s11357-023-00887-2-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tóth, Emese |e verfasserin |4 aut | |
245 | 1 | 0 | |a Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Abstract Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment. | ||
650 | 4 | |a Lung |7 (dpeaa)DE-He213 | |
650 | 4 | |a Autoantibody |7 (dpeaa)DE-He213 | |
650 | 4 | |a IgM |7 (dpeaa)DE-He213 | |
650 | 4 | |a IgG |7 (dpeaa)DE-He213 | |
650 | 4 | |a Multi-producer |7 (dpeaa)DE-He213 | |
650 | 4 | |a Severe COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Mortality |7 (dpeaa)DE-He213 | |
650 | 4 | |a Clinical outcome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Post-COVID |7 (dpeaa)DE-He213 | |
650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
700 | 1 | |a Fagyas, Miklós |4 aut | |
700 | 1 | |a Nagy, Béla |4 aut | |
700 | 1 | |a Siket, Ivetta Mányiné |4 aut | |
700 | 1 | |a Szőke, Blanka |4 aut | |
700 | 1 | |a Mártha, Lilla |4 aut | |
700 | 1 | |a Mahdi, Mohamed |4 aut | |
700 | 1 | |a Erdősi, Gábor |4 aut | |
700 | 1 | |a Pólik, Zsófia |4 aut | |
700 | 1 | |a Kappelmayer, János |4 aut | |
700 | 1 | |a Papp, Zoltán |4 aut | |
700 | 1 | |a Borbély, Attila |4 aut | |
700 | 1 | |a Szabó, Tamás |4 aut | |
700 | 1 | |a Balla, József |4 aut | |
700 | 1 | |a Balla, György |4 aut | |
700 | 1 | |a Bácsi, Attila |4 aut | |
700 | 1 | |a Szekanecz, Zoltán |4 aut | |
700 | 1 | |a Bai, Péter |4 aut | |
700 | 1 | |a Tóth, Attila |0 (orcid)0000-0001-6503-3653 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Age |d New York, NY : Springer Science+Business Media, 1978 |g 46(2023), 2 vom: 01. Sept., Seite 1561-1574 |w (DE-627)SPR018895395 |w (DE-600)2201958-3 |x 1574-4647 |7 nnns |
773 | 1 | 8 | |g volume:46 |g year:2023 |g number:2 |g day:01 |g month:09 |g pages:1561-1574 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11357-023-00887-2 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 46 |j 2023 |e 2 |b 01 |c 09 |h 1561-1574 |